Limits...
Whole-body cryotherapy as adjunct treatment of depressive and anxiety disorders.

Rymaszewska J, Ramsey D, Chładzińska-Kiejna S - Arch. Immunol. Ther. Exp. (Warsz.) (2008)

Bottom Line: The study group was additionally treated with a series of 15 daily visits to a cryogenic chamber (2-3 min, from -160 degrees C to -110 degrees C).The Hamilton's depression rating scale (HDRS) and Hamilton's anxiety rating scale (HARS) were used as the outcome measures.After three weeks, a decrease of at least 50% from the baseline HDRS-17 scores in 34.6% of the study group and 2.9% of the control group and a decrease of at least 50% from the baseline HARS score in 46.2% of the study group and in none of the control group were noted.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Wrocław Medical University, Wrocław, Poland. ankarym@psych.am.wroc.pl

ABSTRACT

Introduction: Rheumatism has been treated using whole-body cryotherapy (WBCT) since the 1970s. The aim of this study was to assess the efficacy of WBCT as an experimental, adjunctive method of treating depressive and anxiety disorders.

Materials and methods: A control (n=34) and a study group (n=26), both consisting of outpatients 18-65 years old with depressive and anxiety disorders (ICD-10), received standard psychopharmacotherapy. The study group was additionally treated with a series of 15 daily visits to a cryogenic chamber (2-3 min, from -160 degrees C to -110 degrees C). The Hamilton's depression rating scale (HDRS) and Hamilton's anxiety rating scale (HARS) were used as the outcome measures.

Results: After three weeks, a decrease of at least 50% from the baseline HDRS-17 scores in 34.6% of the study group and 2.9% of the control group and a decrease of at least 50% from the baseline HARS score in 46.2% of the study group and in none of the control group were noted.

Conclusions: These findings, despite such limitations as a small sample size, suggest a possible role for WBCT as a short-term adjuvant treatment for mood and anxiety disorders.

Show MeSH

Related in: MedlinePlus

Intensity of depressive symptoms within the measure points (HDRS-17 scores).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2734249&req=5

Fig2: Intensity of depressive symptoms within the measure points (HDRS-17 scores).

Mentions: Considering the effects of treatment over the first two weeks, these decreases were significantly greater in the study group (Z= −6.218, p<0.001 and Z= −4.817, p<0.001, respectively). In the third week of treatment (T3–T4) a significant decrease in anxiety symptoms was observed in the control group (Z= −2.307, p<0.03). However, no such change was observed in the severity of depressive symptoms (Z= −0.081, p>0.9). In the study group a significant reduction was noted in both cases (Z= −2.995, p<0.004 and Z= −3.297, p<0.002, respectively). Again, these reductions were significantly greater in the study group (depression: Z= −4.295, p<0.001, anxiety: Z= -1.958, p=0.05). Over the first three weeks of treatment (T1–T4) a significant decrease was noted in the severity of anxiety (Fig. 1; control group: Z= −3.156, p<0.003, study group: Z= −4.436, p<0.001) and depression (control group: Z= −2.146, p<0.033, study group: Z= -4.461, p<0.001; Fig. 2).Fig. 1


Whole-body cryotherapy as adjunct treatment of depressive and anxiety disorders.

Rymaszewska J, Ramsey D, Chładzińska-Kiejna S - Arch. Immunol. Ther. Exp. (Warsz.) (2008)

Intensity of depressive symptoms within the measure points (HDRS-17 scores).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2734249&req=5

Fig2: Intensity of depressive symptoms within the measure points (HDRS-17 scores).
Mentions: Considering the effects of treatment over the first two weeks, these decreases were significantly greater in the study group (Z= −6.218, p<0.001 and Z= −4.817, p<0.001, respectively). In the third week of treatment (T3–T4) a significant decrease in anxiety symptoms was observed in the control group (Z= −2.307, p<0.03). However, no such change was observed in the severity of depressive symptoms (Z= −0.081, p>0.9). In the study group a significant reduction was noted in both cases (Z= −2.995, p<0.004 and Z= −3.297, p<0.002, respectively). Again, these reductions were significantly greater in the study group (depression: Z= −4.295, p<0.001, anxiety: Z= -1.958, p=0.05). Over the first three weeks of treatment (T1–T4) a significant decrease was noted in the severity of anxiety (Fig. 1; control group: Z= −3.156, p<0.003, study group: Z= −4.436, p<0.001) and depression (control group: Z= −2.146, p<0.033, study group: Z= -4.461, p<0.001; Fig. 2).Fig. 1

Bottom Line: The study group was additionally treated with a series of 15 daily visits to a cryogenic chamber (2-3 min, from -160 degrees C to -110 degrees C).The Hamilton's depression rating scale (HDRS) and Hamilton's anxiety rating scale (HARS) were used as the outcome measures.After three weeks, a decrease of at least 50% from the baseline HDRS-17 scores in 34.6% of the study group and 2.9% of the control group and a decrease of at least 50% from the baseline HARS score in 46.2% of the study group and in none of the control group were noted.

View Article: PubMed Central - PubMed

Affiliation: Department of Psychiatry, Wrocław Medical University, Wrocław, Poland. ankarym@psych.am.wroc.pl

ABSTRACT

Introduction: Rheumatism has been treated using whole-body cryotherapy (WBCT) since the 1970s. The aim of this study was to assess the efficacy of WBCT as an experimental, adjunctive method of treating depressive and anxiety disorders.

Materials and methods: A control (n=34) and a study group (n=26), both consisting of outpatients 18-65 years old with depressive and anxiety disorders (ICD-10), received standard psychopharmacotherapy. The study group was additionally treated with a series of 15 daily visits to a cryogenic chamber (2-3 min, from -160 degrees C to -110 degrees C). The Hamilton's depression rating scale (HDRS) and Hamilton's anxiety rating scale (HARS) were used as the outcome measures.

Results: After three weeks, a decrease of at least 50% from the baseline HDRS-17 scores in 34.6% of the study group and 2.9% of the control group and a decrease of at least 50% from the baseline HARS score in 46.2% of the study group and in none of the control group were noted.

Conclusions: These findings, despite such limitations as a small sample size, suggest a possible role for WBCT as a short-term adjuvant treatment for mood and anxiety disorders.

Show MeSH
Related in: MedlinePlus